Affinity Asset Advisors’s Orchestra BioMed OBIO Stock Holding History

Affinity Asset Advisors’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.71M	Sell	402,550 -170,254	-30%	-$725K	0.09%	95
2025 Q4	$2.38M	Sell	572,804 -154,468	-21%	-$623K	0.14%	79
2025 Q3	$1.8M	Buy	+727,272	New	+$2.01M	0.16%	77
2022 Q2	–	Sell	-300,000	Closed	-$2.97M	–	61
2022 Q1	$2.97M	Hold	300,000	–	–	0.48%	31
2021 Q4	$3M	Hold	300,000	–	–	1.09%	34
2021 Q3	$2.97M	Hold	300,000	–	–	0.75%	33
2021 Q2	$3.06M	Buy	300,000 +75,000	+33%	+$776K	1.1%	21
2021 Q1	$2.52M	Buy	225,000 +25,000	+13%	+$304K	0.86%	35
2020 Q4	$2.56M	Buy	+200,000	New	+$2.28M	1.36%	20

Other funds holding OBIO

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

DMKJ

David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return

Affinity Asset Advisors's OBIO Position: Q1 2026 in Review

Affinity Asset Advisors reduced its Orchestra BioMed (OBIO) stake by 30% in Q1 2026, selling an estimated $725K and leaving 402,550 shares worth $1.71M. The position accounts for 0.09% of the portfolio, ranked #95.

Affinity Asset Advisors first reported a position in OBIO in Q4 2020 and has held it in 9 quarters since. The position peaked at $3.06M in Q2 2021. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

Affinity Asset Advisors held 402,550 shares of Orchestra BioMed worth $1.71M as of Q1 2026.
Affinity Asset Advisors sold 170,254 Orchestra BioMed shares in Q1 2026, an estimated $725K.
Orchestra BioMed made up 0.09% of Affinity Asset Advisors's portfolio in Q1 2026, its #95 holding.
Affinity Asset Advisors first reported a position in Orchestra BioMed in Q4 2020 and has held it in 9 quarters since.
Affinity Asset Advisors's Orchestra BioMed position peaked at $3.06M in Q2 2021.
65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.